Abstract
Background
Status epilepticus (SE) is a life-threatening neurologic disorder comprising prolonged and unremitting crisis, and two or more series of seizures without complete intercritical recovery.
Data sources
We reviewed the literature through a Pubmed/Medline research using key words including status epilepticus, antiepileptic drugs and children, in order to revise and compare international/national protocols and to examine pediatric guidelines in SE management.
Results
Neurologic impairment and SE etiology seem to be the most independent risks for mortality. A deep semiologic evaluation is essential to addressing diagnostic work-up. Ematochemical parameters, plasma levels of antiepileptic drugs and clinically oriented toxic/metabolic screening should be mandatory for investigating both causes and effects of SE. Electroencephalography is clearly helpful to characterize focal from generalized SE and to distinguish epileptic events from pseudoseizures, and it is deal to find nonconvulsive SE. Neuroimaging techniques could detect epileptogenic lesions (such as cortical malformations, tumors, demyelinating disorders or strokes) but are common in practice to find negative or controversial results. Pharmacologic management can be essentially arranged in three stages: benzodiazepines for early SE (lasting less than 30 minutes), phenytoin/fosphenytoin, phenobarbital, valproate, levetiracetam or lacosamide for established SE (30–90 minutes), and anesthetics for refractory SE (more than 90 minutes).
Conclusions
Status epilepticus is the most common neurologic emergency in childhood. A systematic diagnostic work-up and a three steps based therapeutic approach is required at this age.
Article PDF
Similar content being viewed by others
References
Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia 1999;40:120–122.
Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006;13:445–450.
Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010;51:676–685.
Guerrini R. Epilepsy in children. Lancet 2006;367:499–524.
Neville BG, Chin RF, Scott RC. Childhood convulsive status epilepticus: epidemiology, management and outcome. Acta Neurol Scand Suppl 2007;186:21–24.
Riviello JJ Jr, Ashwal S, Hirtz D, Glauser T, Ballaban-Gil K, Kelley K, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2006;67:1542–1550.
DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029–1035.
Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998;50:735–741.
Novorol CL, Chin RF, Scott RC. Outcome of convulsive status epilepticus: a review. Arch Dis Child 2007;92:948–951.
Kravljanac R, Jovic N, Djuric M, Jankovic B, Pekmezovic T. Outcome of status epilepticus in children treated in the intensive care unit: a study of 302 cases. Epilepsia 2011;52:358–363.
Pujar SS, Neville BG, Scott RC, Chin RF; North London Epilepsy Research Network. Death within 8 years after childhood convulsive status epilepticus: a population-based study. Brain 2011;134 (Pt 10):2819–2827.
Garzon E, Fernandes RM, Sakamoto AC. Analysis of clinical characteristics and risk factors for mortality in human status epilepticus. Seizure 2003;12:337–345.
Wilder-Smith EP, Lim EC, Teoh HL, Sharma VK, Tan JJ, Chan BP, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore 2005;34:417–420.
Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134 (Pt 10):2802–2818.
Chen JW, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status epilepticus. Acta Neurol Scand 2007;115(4 Suppl):7–15.
Deshpande LS, Lou JK, Mian A, Blair RE, Sombati S, Attkisson E, et al. Time course and mechanism of hippocampal neuronal death in an in vitro model of status epilepticus: role of NMDA receptor activation and NMDA dependent calcium entry. Eur J Pharmacol 2008;583:73–83.
Schauwecker PE. Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain. Exp Neurol 2010;224:207–218.
Ngomba RT, Santolini I, Salt TE, Ferraguti F, Battaglia G, Nicoletti F, et al. Metabotropic glutamate receptors in the thalamocortical network: strategic targets for the treatment of absence epilepsy. Epilepsia 2011;52:1211–1222.
Engel T, Tanaka K, Jimenez-Mateos EM, Caballero-Caballero A, Prehn JH, Henshall DC. Loss of p53 results in protracted electrographic seizures and development of an aggravated epileptic phenotype following status epilepticus. Cell Death Dis 2010;1:e79.
Engel T, Hatazaki S, Tanaka K, Prehn JH, Henshall DC. Deletion of Puma protects hippocampal neurons in a model of severe status epilepticus. Neuroscience 2010;168:443–450.
Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591–602.
Kuteykin-Teplyakov K, Brandt C, Hoffmann K, Löscher W. Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia 2009;50:887–897.
Löscher W. Molecular mechanisms of drug resistance in status epilepticus. Epilepsia 2009;50Suppl 12:19–21.
Fountain NB. Status epilepticus: risk factors and complications. Epilepsia 2000;41Suppl 2:S23–30.
Nandhagopal R. Generalised convulsive status epilepticus: an overview. Postgrad Med J 2006;82:723–732.
Maytal J, Novak G, Ascher C, Bienkowski R. Status epilepticus in children with epilepsy: the role of antiepileptic drug levels in prevention. Pediatrics 1996;98(6 Pt 1):1119–1121.
Barry E, Hauser WA. Status epilepticus and antiepileptic medication levels. Neurology 1994;44:47–50.
Knake S, Hamer HM, Rosenow F. Status epilepticus: a critical review. Epilepsy Behav 2009;15:10–14.
Chin RF, Neville BG, Scott RC. Meningitis is a common cause of convulsive status epilepticus with fever. Arch Dis Child 2005;90:66–69.
Hirtz D, Ashwal S, Berg A, Bettis D, Camfield C, Camfield P, et al. Practice parameter: evaluating a first nonfebrile seizure in children: report of the quality standards subcommittee of the American Academy of Neurology, The Child Neurology Society, and The American Epilepsy Society. Neurology 2000;55:616–623.
Berg AT, Shinnar S, Levy SR, Testa FM. Status epilepticus in children with newly diagnosed epilepsy. Ann Neurol 1999;45:618–623.
Mastrangelo M, Celato A, Leuzzi V. A diagnostic algorithm for the evaluation of early onset genetic-metabolic epileptic encephalopathies. Eur J Paediatr Neurol 2012;16:179–191.
Abdel Baki SG, Omurtag A, Fenton AA, Zehtabchi S. The new wave: time to bring EEG to the emergency department. Int J Emerg Med 2011;4:36.
Brenner RP. EEG in convulsive and nonconvulsive status epilepticus. J Clin Neurophysiol 2004;21:319–331.
Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005;22:79–91.
Ferrie CD, Caraballo R, Covanis A, Demirbilek V, Dervent A, Fejerman N, et al. Autonomic status epilepticus in Panayiotopoulos syndrome and other childhood and adult epilepsies: a consensus view. Epilepsia 2007;48:1165–1172.
Nickels K, Wirrell E. Electrical status epilepticus in sleep. Semin Pediatr Neurol 2008;15:50–60.
Scott RC, Gadian DG, King MD, Chong WK, Cox TC, Neville BG, et al. Magnetic resonance imaging findings within 5 days of status epilepticus in childhood. Brain 2002;125(Pt 9):1951–1959.
Minicucci F, Muscas G, Perucca E, Capovilla G, Vigevano F, Tinuper P. Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia 2006;47Suppl 5:9–15.
Treiman DM. The role of benzodiazepines in the management of status epilepticus. Neurology 1990;40(5 Suppl 2):32–42.
Sofou K, Kristjánsdóttir R, Papachatzakis NE, Ahmadzadeh A, Uvebrant P. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol 2009;24:918–926.
Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics 2008;121:e58–64.
Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000;321:83–86.
Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999;353:623–626.
Gospe SM Jr. Neonatal vitamin-responsive epileptic encephalopathies. Chang Gung Med J 2010;33:1–12.
Eriksson K, Keränen T, Kälviäinen R. Fosphenytoin. Expert Opin Drug Metab Toxicol 2009;5:695–701.
Yamamoto LG, Yim GK. The role of intravenous valproic acid in status epilepticus. Pediatr Emerg Care 2000;16:296–298.
Sheth RD, Gidal BE. Intravenous valproic acid for myoclonic status epilepticus. Neurology 2000;54:1201.
Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000;54:2188–2189.
Embacher N, Karner E, Wanschitz J, Beer R, Trinka E. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol 2006;13:e5–6.
Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009;14:215–218.
Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011;52:e148–152.
Shiloh-Malawsky Y, Fan Z, Greenwood R, Tennison M. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure 2011;20:586–588.
Tarulli A, Drislane FW. The use of topiramate in refractory status epilepticus. Neurology 2004;62:837.
Kahriman M, Minecan D, Kutluay E, Selwa L, Beydoun A. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia 2003;44:1353–1356.
Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav 2003;4:757–760.
Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia 2006;47:1070–1071.
Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002;36:1453–1456.
van Gestel JP, Blussé van Oud-Alblas HJ, Malingré M, Ververs FF, Braun KP, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005;65:591–592.
Schmitt FC, Dehnicke C, Merschhemke M, Meencke HJ. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav 2010;17:565–568.
Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46:967–969.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mastrangelo, M., Celato, A. Diagnostic work-up and therapeutic options in management of pediatric status epilepticus. World J Pediatr 8, 109–115 (2012). https://doi.org/10.1007/s12519-012-0348-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-012-0348-2